6.98
Iovance Biotherapeutics Inc stock is traded at $6.98, with a volume of 17.38M.
It is up +7.06% in the last 24 hours and up +77.61% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
See More
Previous Close:
$6.52
Open:
$6.52
24h Volume:
17.38M
Relative Volume:
1.10
Market Cap:
$3.16B
Revenue:
$285.55M
Net Income/Loss:
$-353.86M
P/E Ratio:
-7.3466
EPS:
-0.9501
Net Cash Flow:
$-305.02M
1W Performance:
+10.09%
1M Performance:
+77.61%
6M Performance:
+171.60%
1Y Performance:
+184.90%
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IOVA
Iovance Biotherapeutics Inc
|
6.98 | 3.05B | 285.55M | -353.86M | -305.02M | -0.9501 |
|
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Upgrade | Citizens | Mkt Perform → Mkt Outperform |
| Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
| May-16-25 | Downgrade | UBS | Buy → Neutral |
| May-12-25 | Downgrade | Truist | Buy → Hold |
| May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
GSA Capital Partners LLP Buys New Holdings in Iovance Biotherapeutics, Inc. $IOVA - marketbeat.com
Bank of America Corp DE Sells 5,787,694 Shares of Iovance Biotherapeutics, Inc. $IOVA - marketbeat.com
Iovance Biotherapeutics, Inc. stock Analysis: 130% Rally & Overbought Signals 2026 - The Cryptonomist
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance? - Yahoo Finance
Iovance (IOVA) Q2 2026 Earnings Call Transcript - AOL.com
IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Chart - ChartMill
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 12-Month HighHere's What Happened - marketbeat.com
Iovance Biotherapeutics stock hits 52-week high at 6.94 USD By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics stock hits 52-week high at 6.94 USD - Investing.com
Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Iovance Biotherapeutics, Inc. (IOVA) Latest Stock News & Headlines - Yahoo Finance
IOVA Stock Quote Price and Forecast - CNN
IOVA Stock Price Prediction 2025-2026 | Iovance Biotherapeutics Inc Forecast - 24/7 Wall St.
Iovance Biotherapeutics (IOVA) Is Up 48.3% After Narrowing Losses And Reaffirming 2026 Revenue Guidance - Sahm
Iovance Biotherapeutics (IOVA) Stock Looks Fairly Valued Despite 222% Returns - Sahm
Hennion & Walsh Asset Management Inc. Grows Stock Position in Iovance Biotherapeutics, Inc. $IOVA - marketbeat.com
Iovance Biotherapeutics (IOVA) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Is Iovance Biotherapeutics (IOVA) Undervalued On Q2 Earnings And Reaffirmed Guidance? - Sahm
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher? - The Motley Fool
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher? - The Motley Fool
Why Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Back in Market Conversation? - Kalkine Media
Weekly Recap: IOV-LUN-202 enrollment and Q2 2026 revenue jump - TradingView
Dimensional Fund Advisors LP Purchases 1,106,592 Shares of Iovance Biotherapeutics, Inc. $IOVA - marketbeat.com
What is HC Wainwright's Forecast for IOVA Q3 Earnings? - MarketBeat
Earnings Beat: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - moomoo.com
Iovance Biotherapeutics (NASDAQ:IOVA) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Iovance Biotherapeutics Stock Price Forecast. Should You Buy IOVA? - StockInvest.us
Iovance Biotherapeutics (NASDAQ:IOVA) Given New $8.00 Price Target at Citizens Jmp - MarketBeat
$Iovance Biotherapeutics (IOVA.US)$ - Moomoo
State Street Corporation (NYSE: STT) discloses 5.5% Iovance Biotherapeutics stake - Stock Titan
Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect? - Yahoo Finance
A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $7 to $13 - Moomoo
Iovance Biotherapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Form 8K Iovance Biotherapeutics Inc For: 6 August By Investing.com - Investing.com South Africa
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Exploring a 44.93% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Iovance Biotherapeutics Inc (IOVA) Stock News Today - TradingKey
Iovance Biotherapeutics Inc (IOVA) (Q2 2026) Earnings Call Highl - GuruFocus
Iovance Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 100% Upside - TradingView
Iovance Biotherapeutics Inc (IOVA) (Q2 2026) Earnings Call Highlights: Record Revenue and ... - Yahoo Finance
Iovance Biotherapeutics stock hits 52-week high at $5.97 By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics (NASDAQ: IOVA) files updated August 2026 presentation - Stock Titan
Iovance Biotherapeutics Q2 Earnings Call Highlights - MarketBeat
Iovance Biotherapeutics (IOVA) Pops 43% on Stellar Q2. Here’s What Comes Next - Yahoo Finance
IovanceStock Soars On Q2 EarningsCritical Data In Melanoma, NSCLC Due September - Seeking Alpha
Iovance Biotherapeutics (IOVA) Shares Surge 40% on Strong Q2; Ma - GuruFocus
Earnings call transcript: Iovance beats Q2 2026 estimates, shares jump 30% - Investing.com
Iovance shares surge 39% as Amtagvi Q2 revenue and margins surpass expectations - TechStock²
Iovance Biotherapeutics (IOVA) Revises 2026 Revenue Outlook Amid Strong Q2 Sales - GuruFocus
Why Iovance Biotherapeutics (IOVA) Stock Is Up Today - Quiver Quantitative
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):